Kiva Confections, a Californian medical cannabis company, has just introduced its new chocolate bars high in cannabidiol (CBD) and made from 100 percent whole plant cannabis. Recent anecdotal research has shown CBD to be an effective agent against systemic lupus erythematosus (SLE) and many other diseases. CBD and tetrahydrocannabinol (THC) are the two main ingredients of the […]

by

JUDY WOODRUFF:  With recreational marijuana now legal in eight states, a serious health and safety question about the potency of the psychoactive drug in cannabis, known as THC, are emerging.  In Colorado, some marijuana products contain 90 percent pure THC, with little research documenting the physical and mental effects on consumers. This week, the state’s […]

by

(Photo of Dr. Mac Burnham-Courtesy Ontario Brain Institute) As marijuana marches towards legalization in Canada, researchers are digging ever deeper into its potential therapeutic benefits. For people suffering from epilepsy it could mean reaching back to the wisdom of the ancients to deliver a modern form of relief. For thousands of years, cannabis has been […]

by

(Photo of Dr. Mac Burnham-Courtesy Ontario Brain Institute) As marijuana marches towards legalization in Canada, researchers are digging ever deeper into its potential therapeutic benefits. For people suffering from epilepsy it could mean reaching back to the wisdom of the ancients to deliver a modern form of relief. For thousands of years, cannabis has been […]

by

Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary ActionCapsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA SynthesisSecond Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 14, 2016 — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus […]

by

British-based GW Pharmaceuticals announced positive Phase 3 study results of its drug Epidiolex for two treatment-resistant forms of epilepsy, at the 70th Annual Meeting of the American Epilepsy Society in Houston. Epidiolex is an oral formulation of cannabidiol (or CBD), one of 500 compounds found in cannabis.  Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does not have a […]

by

SEATTLE, WA — (Marketwired) — 12/14/16 — CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Medical Marijuana Inc.’s (OTC PINK: MJNA) global position in the burgeoning market for hemp-derived, cannabidiol (CBD)-based products. According to the Hemp Industry Association, annual retail sales […]

by

LOS ANGELES–(BUSINESS WIRE)–Phytecs is expanding its preclinical research program on its novel fluorinated cannabidiol, HUF-101, along with its family of related drug molecules developed by noted medicinal chemist and Phytecs Director of Global Research, Prof. Raphael Mechoulam of The Hebrew University of Jerusalem. A new preclinical study found HUF-101 effective in mice models predictive of […]

by

Please note that Epilepsy Research UK does not endorse/promote individual epilepsy treatments or pharmaceutical companies. Treatment with cannabidiol (CBD) improves the frequency and severity of seizures in children and adults with epilepsy, according to research presented at the American Epilepsy Society annual meeting in Huston, Texas. The findings are based on an open label,* expanded access […]

by

Please note that Epilepsy Research UK does not endorse/promote individual epilepsy treatments or pharmaceutical companies. Treatment with cannabidiol (CBD) improves the frequency and severity of seizures in children and adults with epilepsy, according to research presented at the American Epilepsy Society annual meeting in Huston, Texas. The findings are based on an open label,* expanded access […]

by

Please note that Epilepsy Research UK does not endorse/promote individual epilepsy treatments or pharmaceutical companies. Treatment with cannabidiol (CBD) improves the frequency and severity of seizures in children and adults with epilepsy, according to research presented at the American Epilepsy Society annual meeting in Huston, Texas. The findings are based on an open label,* expanded access […]

by

DEVON, Pa., Nov. 21, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that Armando Anido, Chairman and CEO, and other members of Company management will participate at various upcoming investor meetings and conferences in November, including:Oppenheimer Life Sciences […]

by